Vioxx Woes May Reveal FDA's Flaws
January 28, 2005 14:51

The controversy over the drug Vioxx not only left millions of consumers confused about how to safely treat pain, but it may have exposed serious flaws in the federal government's ability to ensure drug safety. That's... (Read Article)

(BUSINESS WIRE)--Jan. 28, 2005--Noven Pharmaceuticals, Inc. (NASDAQ:NOVN) announced that the U.S. Food & Drug Administration (FDA) today denied... (Read Article)

Drug maker Eli Lilly and Co., together with partner Boehringer Ingelheim Pharmaceuticals Inc., said Friday that Lilly has withdrawn its application seeking Food and Drug Administration approval to market duloxetine as a treatment for stress urinary incontinence, or SUI.

"On Jan. 15, the Rocky Mountain News editorialized that it was 'Time to tackle tort.' But the editorial was based on untrue premises: that the legal system, rather than insurance companies' practices, increases insurance premiums, and that Americans worry more... (Read Article)